BCA101 Trial for Cancer
Phase 1
292
about 7 years
18+
15 sites in CA, FL, MA +8
What this study is about
Researchers are testing the safety and how well BCA101 works when used alone or with Pembrolizumab in people with advanced cancers driven by EGFR. The treatment type is medication, and it's being tested on adults. The trial will last about 2556 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BCA101
- 2.Take Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Incidence of Dose Limiting Toxicities (DLTs), Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs, Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs
Secondary: AUC of BCA101 and pembrolizumab, Clinical Benefit Rate, Cmax of BCA101 and pembrolizumab, Duration of Response, Half-life of BCA101 and pembrolizumab, Objective Response Rate, Overall Survival, Progression free survival
Oncology